| Family: | F/m Investments |
| Name: | F/m Emerald Life Sciences Innovation ETF |
| Inception Date: | 30-Oct-2024 |
| Termination Date: | |
| Investment Objective: | F/m Emerald Life Sciences Innovation ETF is an actively managed ETF that invests primarily in equity securities of life sciences companies. The fund selects investments based on breakthrough science and innovation, targeting unique growth opportunities across companies of any size. The Fund's investments include common and preferred stock, other investment companies, and depositary receipts. It may also invest in private placements, warrants, rights, and initial public offerings. |
| Prospectus | |
| Top 10 Holdings | ||
| Travere Therapeutics Inc | TVTX | 7.8700% |
| Spyre Therapeutics Inc | SYRE | 7.1900% |
| Cogent Biosciences Inc | COGT | 7.1600% |
| LivaNova PLC | LIVN | 6.9100% |
| Guardant Health Inc | GH | 5.7800% |
| Corcept Therapeutics Inc | CORT | 5.4200% |
| Mirum Pharmaceuticals Inc | MIRM | 4.9800% |
| Billiontoone Inc | BLLN | 4.6100% |
| Cytokinetics Inc | CYTK | 4.0400% |
| United Therapeutics Corp | UTHR | 3.4600% |
| Top 10 Holdings Weight: | 57.4% |
| Number of Holdings: | 39 |
| Shares Outstanding: | 2,727,035 |
| Total Net Assets: | 122,458,600 |
| NAV: | 44.94 |
| Net Expense Ratio: | 0.54% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
